近日，国家医保局针对少数企业部分药品垄断控销、虚增成本、以缺逼涨等问题，持续强化药品价格常态化监管。自2023年初以来，国家医保局综合运用监测预警、函询约谈、信用评价、信息披露等手段，有力有效处置一批通过虚抬原料药价格、倒逼制剂价格上涨的企业。据悉，2023年约谈药品平均降价幅度超过40%，为广大患者带来实实在在的降价红利。
英文翻译：
News content:
Recently, the National Medical Security Bureau has strengthened the normalized supervision of drug prices to address issues such as monopoly control, inflated costs, and price hikes caused by shortages. Since the beginning of 2023, the bureau has employed various measures including monitoring warnings, letter inquiries, credit evaluations, and information disclosure to effectively deal with enterprises that artificially raise the prices of raw materials and force the upward trend of formulated drugs. It is reported that the average price reduction of negotiated drugs in 2023 exceeds 40%, bringing tangible price discounts for patients.
Keywords: Drug monopoly, price reduction, normalized supervision
【来源】http://www.chinanews.com/gn/2024/01-05/10140901.shtml
Views: 1